1,494 results on '"Arnold, Matthew"'
Search Results
2. The US 'surge' as a collaborative corrective for Iraq
3. Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses
4. North Carolina's nonconformity to federal bonus depreciation: mechanics and planning opportunities
5. A Reconfigurable Over-the-Air Chamber for Testing Multi-Antenna Wireless Devices
6. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses
7. A view to a pill: 5 breakthroughs at the intersection of devices and diagnostics that promise to make healthcare more effective and accessible
8. DTC drain: consumer ad spend fell sharply in 2012 as the number of mass-market blockbusters continued to dwindle and marketers shifted their focus away from TV and toward digital channels. Meanwhile, as Matthew Arnold finds, the debate over the pros and cons of DTC is still raging, even as evidence of its merits accumulates
9. Sanofi proves its pluck
10. From AIC to Z: sites like Novo Nordisk's Cornerstones4Care are bringing full-spectrum segmentation to the task of bolstering adherence and being there for the patient, reports Matthew Arnold
11. The APP avant-garde: medical devices marrying apps and consumer electronics are setting off a wave that will revolutionize chronic-disease management--and could upturn biopharma business models, Matthew Arnold reports
12. DTC: beyond the block-buster: the mass-market, TV-and-print DTC formula is going the way of the vanishing primary care blockbusters it was designed to boost as new media and 'niche products fill the breach Matthew Arnold reports
13. Tailor made marketing: aided by the digital revolution, patient marketing programs are getting increasingly personal, with greater levels of customization aimed at differentiating products and keeping patients on therapy Matthew Arnold reports
14. Screen play: the suddenly hot market for high-risk HPV tests, where Roche diagnostics is launching against two entrenched brands, offers a window into a future of personalized medicine and the convergence of drugs, diagnostics and devices. Matthew Arnold reports
15. Cliff notes: drug revenues barely kept pace last year, as other indicators like numbers of protected brands and reps have decreased, amid the overall trend of industry consolidation. With more products set to take the plunge over the patent cliff, analysts say margins are due to be tight for the foreseeable future. Marc Iskowitz and Matthew Arnold report
16. Code red for DTC? DTC spending continues to slide, and with many of the blockbuster, mass-market drugs that have sustained it over the past decade set to lose patent protection, the print-and-TV-advertising formula seems sure to go with it. Matthew Arnold reports
17. Class apps: mobile apps are the future of patient education and disease management, promising better tracking, improved adherence and richer patient-doctor dialogue, reports Matthew Arnold
18. Pharma's got a brand new bag: pharmas aren't merely downsizing reps, they're rethinking the detail and installing specialized sales forces, breaking them up into regions and making outcomes king, Matthew Arnold reports
19. Thinking past the pill: Pfizer is investing heavily in adherence, putting patient support programs on equal footing with some of its drugs, Matthew Arnold reports
20. Out of the box: the formerly sleepy business of marketing devices and diagnostics is getting much savvier amid technological innovations, empowered patients and an evermore complicated healthcare system, reports
21. Flat is the new up: after a sharp downturn, consumer ad outlays have stabilized. Advertisers are spending again, but with budgets under pressure, they're seeking deals, and amid thinning pipelines, they're supporting mature blockbusters later in their lifecycles. Matthew Arnold reports on the trends
22. A bountiful alpine pipeline
23. A new Dawn: the healthcare reform legislation inching toward the president's desk will mean big changes for the pharmaceutical industry, whatever its final form. Matthew Arnold takes a look at what's ahead
24. Course correction
25. Between screens: a shift in DTC: drug advertisers may be saving the TV industry, but they're moving beyond dabbling in digital
26. Electrochemical energy storage on nanoporous copper sponge
27. Just the challenge we need? The Democrats are mixing up some strong medicine for the pharma industry. Matthew Arnold performs a risk-benefit analysis
28. Poll reversal: it's an Alice in Wonderland election for the industry, which finds itself favoring the Democratic candidate after eight years of alignment with the party of business. Would pharma fare better under Obama? Matthew Arnold looks at the candidates and their positions
29. Lesson plans: CME support is likely to slump amid regulatory uncertainty and a multi-pronged assault on alleged industry influence
30. Steady migration: slowly but surely, consumer advertising and promotion is getting smarter and more targeted as marketers broaden their media plans to cope with a dearth of blockbusters to birth. Matthew Arnold reports on the trends and figures for DTC
31. Merck sets science in motion
32. Electile dysfunction: it's election season once again, and everybody's running against Big Pharma. But the industry has bigger problems
33. Biotech blurring: big pharma has long looked to biotechs to help fatten pipelines, but one company has experienced the benefits of keeping things in-house. Matthew Arnold looks at how Wyeth came up with another way to conduct business
34. Top 20 pharma companies: while the US saw a rebound in prescription drug growth in 2006, few companies are sitting pretty. Matthew Arnold charts the trends, events, stories and numbers of the biggest players
35. DTC the first 10 years: so much has happened since Claritin's 'Blue Skies' spots ushered in a new era of consumer drug advertising that it's difficult to believe the DTC adventure is only a decade old. Matthew Arnold charts the key milestones, players and campaigns, and looks ahead to the future of DTC
36. House of hearings: with the Democrats set to take control of Congress, the new guard of committee leadership presents a mixed-to-bleak picture for pharma industry interests
37. Interactive forces: Merck has taken the hi-tech route to improving efficiency in the field, while other firms experiment with promising new approaches to targeting and detailing physicians
38. Drug money: in an increasingly competitive and strictly regulated market, pharmaceutical marketers are turning to original photography to differentiate their products
39. Publicis Healthcare Communications Group: the medical advertising behemoth completes a reorganization and rolls on with major-league brands
40. The science of DTC: Pharma once again has a spring in its step about consumer campaigns. Only this time, beaches and bold efficacy claims have been replaced by lab coats and risk information, as Merck and others amass data on how viewers absorb TV ads
41. Flexible forces
42. The hard sell: when the new Medicare Prescription Drug Benefit takes effect in January, government will replace the individual consumer as pharma's biggest customer. Onlookers hope that both industry and consumers will come out on top. But first there is the small matter of persuading 30 million Americans to enroll
43. New channels in TV
44. Changing channels
45. In the face of crisis: the COX-2 crisis has rocked the industry, with intense scrutiny from the media and the numerous stakeholders. Matthew Arnold compares the crisis PR efforts of Merck and Pfizer and looks at how other pharmas can learn from this episode to better shape their future communications strategies
46. Uncertain term: while the industry's initial response to the re-election of President George W. Bush has been positive, there are still unresolved issues, such as drug importation from Canada, that cloud pharma's security in 2005
47. The hidden prescribers: while pharmaceutical companies continue to target fewer high-prescribing physicians with less time than ever, an increasingly important segment of healthcare professionals is going largely neglected. Matthew Arnold looks at how companies can harness the growing clout of physician assistants and nurse practitioners
48. The agency conundrum: the challenges facing medical advertising agencies continue to mount, but business and morale remain intact. Matthew Arnold looks at the trends of the past year and how firms are squaring up to the future
49. Directing compliance: patient non-compliance in the statin category alone costs pharma companies billions in lost revenues. Matthew Arnold looks at how Pfizer and others are pushing the boundaries of relationship marketing to keep patients on board and on track
50. PR: the DTC you don't see: there was a time when communications professionals languished on the fringe of the pharma and biotech marketing mix, called on only to deliver bad news and defuse crises. But now, with the increasing primacy of the consumer, proliferation of constituencies and a wave of restructurings, PR is emerging from the shadows as a strategic force
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.